Modalis Therapeutics Corporation (JP:4883) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Modalis Therapeutics Corporation has announced a strategic plan to prioritize their leading AAV therapeutics program and restructure their U.S. subsidiary, leading to a reduction of operating expenses by downsizing personnel. The company is focusing on obtaining IND clearance for their MDL-101 clinical trial and expects these changes to reduce expenses by 35-40 million yen for the fiscal year ending December 31, 2024.
For further insights into JP:4883 stock, check out TipRanks’ Stock Analysis page.